What Is Tavapadon? Understanding This New Approach for Managing Parkinson’s Motor Symptoms

yet. The selective approach also appears to result in lower rates of certain D2/D3-related issues like impulse control disorders or excessive sleepiness in the trial data, though individual experiences vary and more real-world use will provide additional clarity.

Key Findings from Clinical Studies

The TEMPO trials involved hundreds of participants and delivered consistent insights:

In early Parkinson’s (TEMPO-1 and TEMPO-2), tavapadon as monotherapy led to meaningful improvements in motor symptoms and daily activities compared to placebo, as measured by standardized scales.

In people already on levodopa with motor fluctuations (